



PROGRAMME

5ÈME ÉDITION 2026

CONGRÈS EN HÉMATOLOGIE
du 14 au 16 octobre 2026

SORBONNE UNIVERSITÉ
AUDITORIUM DU CICSU, 75005 PARIS



Mandatée par
l'association ARCADE

LE COMITÉ SCIENTIFIQUE



Présidente : **Mauricette MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)

- **Amine BELHABRI** (Hématologue, Centre Léon Bérard, Lyon)
- **Sylvain CHOQUET** (Hématologue, Hôpital Pitié-Salpêtrière, Paris)
- **Jean-Jacques KILADJIAN** (Hématologue, Hôpital Saint-Louis, Paris)
- **Xavier LELEU** (Hématologue, Centre Hospitalier Universitaire de Poitiers, Poitiers)
- **François-Xavier MAHON** (Hématologue, Institut Bergonié, Bordeaux)
- **Anne-Sophie MICHALLET** (Hématologue, Centre Léon Bérard, Lyon)
- **Sophie PARK** (Hématologue, Centre Hospitalier Universitaire Grenoble Alpes, Grenoble)
- **Christian RECHER** (Hématologue, Institut Universitaire du Cancer de Toulouse, Toulouse)
- **Philippe ROUSSELOT** (Hématologue, Centre Hospitalier de Versailles, Versailles)
- **Pierre SESQUES** (Hématologue, Centre Hospitalier Lyon Sud, Lyon)

Wednesday 14th october 2026

09h30 - 10h00 OPENING

10h00 - 10h30 INTRODUCTION

Mauricette MICHALLET (President of the Scientific Committee), (Hematology, Lyon)

- What are the innovations in myeloid diseases since the last SOHO France 2025 conference?

Hagop KANTARJIAN (Oncology Hematology, Houston - USA)

- The latest news from SOHO

Janet CESAK (Executive director SOHO - USA)

10h30 - 11h45 SESSION 1: MYELOPROLIFERATIVE NEOPLASMS

Chair: Jean-Jacques KILADJIAN (Hematology, Paris)

- Essential thrombocythemia: from therapeutic frugality to new horizons

Jean-Jacques KILADJIAN (Hematology, Paris) – 20 min

- Skin carcinomas complicating treatments for NMPs

Hélène PASQUER (Hematology, Paris) – 20 min

- Contribution of AI in the NMP

Vincent ALCAZER (Hematology, Pierre-Bénite) – 20 min

- Discussion – 15 min

11h45 - 12h45

SYMPOSIUM: TAILORED THERAPEUTIC STRATEGIES FOR MYELOFIBROSIS PATIENTS WITH CYTOPENIA, WHERE WE STAND IN 2026?

Chair: Mauricette MICHALLET (President of the Scientific Committee), (Hematology, Lyon)

- Introduction

Mauricette MICHALLET (Hematology, Lyon) – 05 min

- Addressing Cytopenias in Myelofibrosis: From Assessment to Treatment

Laurence LEGROS (Hematology, Kremlin-Bicêtre) – 20 min

- Optimizing Therapeutic Strategies for Clinical Practice

Eolia BRISSOT (Hematology, Paris) – 20 min

- Table ronde - 15 min

GSK

12h45 - 13h45

LUNCH BREAK & MEET OUR PARTNERS



13h45 - 15h00

SESSION 2 : MYELOYDYSPLASTIC SYNDROMES

Chair: Sophie PARK (Hematology, Grenoble)

- Management of clonal hematopoiesis in clinical practice: GFM recommendations

Aline RENNEVILLE (Medical Biology, Gustave Roussy, Villejuif) – 20 min

- Optimization of pre and post transplantation therapies in mds

Marie ROBIN (Hematology, Paris) – 20 min

- How to treat CMML: should we target stem or differentiated cells?

Christophe WILLEKENS (Hematology, Villejuif) – 20 min

- Discussion – 15 min

15h00 - 15h30

CALL FOR ABSTRACT

PROGRAMME

- 15h30 - 16h30 SYMPOSIUM: CHRONIC MYELOID LEUKEMIA AND MYELOFIBROSIS: RETHINKING TODAY'S AND TOMORROW'S THERAPEUTIC PATHWAYS**
Chair: Laurence LEGROS (Hematology, Kremlin-Bicêtre)
- Introduction
- Laurence LEGROS (Hematology, Kremlin-Bicêtre) – 05 min
- Myelofibrosis in France: Navigating Current Treatment Options and Future Innovations
- Jose Miguel TORREGROSA (Hematology, Poitiers) – 25 min
- From Treatment Initiation to Long-Term objectives: Redefining the Treatment Strategy in CML
- Valérie COITEUX (Hematology, Lille) – 25 min
- Conclusion
- Laurence LEGROS (Hematology, Kremlin-Bicêtre) – 05 min
- 16h30 - 16h50 COFFEE BREAK & MEET OUR PARTNERS** 
- 16h50 - 17h20 THE TREATMENT PROTOCOL FOR AML AT MASSACHUSETTS GENERAL HOSPITAL**
Amir FATHI (Hematology, Boston - USA)
- 17h20 - 18h35 SESSION 3: ACUTE MYELOID LEUKEMIA**
Chair: Amine BELHABRI (Hematology, Lyon)
- Functional precision medicine for acute myeloid leukemia
- Kevin BOUMEGHAR (Hematology, Paris) – 20 min
- BIG Experience in France: results of BIG-1 and future BIG-2 program
- Sarah BERTOLI (Hematology, Toulouse) – 20 min
- Results from PARADIGM study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia
- Amir FATHI (Hematology, Boston - USA) – 20 min
- Discussion – 15 min

Thursday 15th october 2026

09h00- 09h30 OPENING

- 09h30 - 10h25 SESSION 4: ACUTE LYMPHOBLASTIC LEUKEMIA**
Chair: Aurélie CABANNES (Hematology, Versailles)
- First results of the ALL TARGET observatory
- Aurélie CABANNES (Hematology, Versailles) – 15 min
- GRAALL recommendations for relapsed ALL
- Marie BALSAT (Hematology, Lyon) – 15 min
- New development of immunotherapies in B-ALL
- Nicolas BOISSEL (Hematology, Paris) – 15 min
- Discussion – 15 min

10h25 - 10h45 COFFEE BREAK & MEET OUR PARTNERS 

10h45 - 11h15 CALL FOR ABSTRACT

PROGRAMME

11h15 - 12h30 SESSION 5: CAR-T CELLS

Chair: Pierre SESQUES (Hematology, Lyon)

- Estimating the real price of CAR-T cells in France: from list price to net price

Carole-Anne BRUGERE (Calym/Hematology, Lyon) – 15 min

- Recommendations from the LYSA centered on the place of the CAR-T cells and data on the L2: comparison vs SOC & Axi-liso: sequence?

Benoît TESSOULIN (Hematology, Nantes) – 15 min

- Impact of T cell characteristics on CAR-T cell therapy / Fitness of T in the CAR-T cells? Present and future

Estelle BOURBON (Hematology, Lyon) – 15 min

- MM: CAR-T cells then bispecific? Bispecific then CAR-T cells? Upcoming sequence?

Alexis TALBOT (Immuno-hematology, Paris) – 15 min

- Discussion – 15 min

12h30 - 13h45 LUNCH BREAK & MEET OUR PARTNERS



13h45 - 14h45 LET'S TALK : QUESTIONS FROM INTERNS TO THE EXPERTS

14h45 - 16h10 SESSION 6: MULTIPLE MYELOMA

Chair: Xavier LELEU (Hematology, Poitiers)

- Towards personalized medicine and cure in multiple myeloma: precision biomarkers and beyond

Anaïs SCHAVGOULIDZE (Medical biology, Toulouse) – 15 min

- Response or resistance! Based on interesting data from RESISTEC. Do we have a predictive response marker, is it useful for real life?

Ludovic MARTINET (Research, Toulouse) – 15 min

- NDMM TE and TI. The IT will replace the autograft, can you convince us?

Cyrille TOUZEAU (Hematology, Nantes) – 15 min

- Tomorrow's IT, new ADCs, new CAR-T, Trispe. With the MAJESTEC 3 and TEC LILLE data, do we still need to develop always more, for what? What are the limits of current TTTs that justify developing more, whether it is safety, efficacy, or cost?

Alexis TALBOT (Immuno-hematology, Paris) – 15 min

- Discussion – 15 min

16h10 - 16h30 COFFEE BREAK & MEET OUR PARTNERS



16h30 - 17h00 LAST CALL FOR ABSTRACT

17h00 - 18h00 SESSION 7: LYMPHOMAS

Chair: Sylvain CHOQUET (Hematology, Paris)

- Primary mediastinal NHL

Vincent CAMUS (Hematology, Rouen) – 15 min

- Relapse/refractory Hodgkin lymphoma

Cédric ROSSI (Hematology, Dijon) – 15 min

- Intravascular NHL

Antoine BONNET (Hematology, Vannes) – 15 min

- Discussion – 15 min

18h00 - 19h00 SOCIAL GATHERING



Friday 16th october 2026

09h00 - 09h30 OPENING

09h30 - 10h45 SESSION 8: CHRONIC MYELOID LEUKEMIA

Chair: François-Xavier MAHON (Hematology, Bordeaux)

- Development of machine learning applied to CML: prognostic and predictive factors

Vincent ALCAZER (Hematology, Pierre-Bénite) – 20 min

- New molecules in CML

François-Xavier MAHON (Hematology, Bordeaux) – 20 min

- Individualizing front line therapy of chronic phase CML

Delphine REA (Hematology, Paris) - 20 min

- Discussion – 15 min

10h45 - 11h00 COFFEE BREAK & MEET OUR PARTNERS



11h00 - 12h15 SESSION 09: CHRONIC LYMPHOCYTIC LEUKEMIA

Chair: Anne-Sophie MICHALLET (Hematology, Lyon)

- Should all patients be treated with a fixed duration of CLL as a first-line treatment?

Emmanuelle FERRANT (Hematology, Lyon) – 20 min

- Is there hope for treating Richter syndrome with new innovative therapies?

Pierre FEUGIER (Hematology, Nancy) – 20 min

- Is immunochemotherapy still the gold standard for first-line treatment in MW?

Cécile TOMOWIAK (Hematology, Poitiers) – 20 min

- Discussion – 15 min

12h15 - 12h25 AWARD CEREMONY - CALL FOR ABSTRACT

12h25 - 13h40 SESSION 10: CELL THERAPY AND TRANSPLANTATION

Follow up and treatments after allo-HSCT for hematological malignancies

Chair: Anne HUYNH (SFGM-TC president), (Hematology and Transplantation, Toulouse)

- Post allo-HSCT monitoring?

Léonardo MAGRO (Hematology and Transplantation, Lille) - 20 min

- Prophylactic treatments after allo-HSCT

Raynier DEVILLIER (Hematology and Transplantation, Marseille) - 20 min

- Treatments of relapse after allo-HSCT

Michael LOSCHI (Hematology and Transplantation, Nice) - 20 min

- Discussion – 15 min

13h40 - 13h50 TAKE HOME MESSAGE